European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
ROCKVILLE, Md., May 10, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
